FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the development of a therapeutic agent for improving resistance of mammals to supercooling. Agent comprises a pharmaceutical composition of preparations containing 0.78–1.18 wt. % of propranolol, 0.015–0.024 wt. % of reserpine, 0.078–0.12 wt. % of ivabradine, 0.098–0.18 wt. % of diphenhydramine, 0.025–0.035 wt. % of pericyazine, 0.25–0.35 wt. % of serotonin hydrochloride, 0.07–0.12 wt. % of propycil, 0.07–0.16 wt. % of magnesium sulfate, 98–98.61 wt. % of pharmaceutically acceptable solvent, also comprises a perfluorocarbon emulsion. Also provided is a method for improving resistance of a mammalian organism to supercooling, comprising administering a therapeutically effective amount of the agent.
EFFECT: technical result is an improved resistance of cells of vital organs and tissues to supercooling.
9 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS INCLUDING PERFLUORIDECARBON EMULSION (VARIANTS), ITS USE AND METHOD OF CREATING REVERSIBLE PHARMACOLOGICALLY INDUCED HYPOMETABOLISM AND HYPOTHERMIA | 2017 |
|
RU2669398C1 |
| MEANS COMPRISING A FAT EMULSION (VARIANTS), ITS USE AND A METHOD FOR INCREASING THE RESISTANCE OF A MAMMALIAN ORGANISM TO SUPERCOOLING | 2017 |
|
RU2668375C1 |
| MEANS INCLUDING FAT EMULSION (VARIANTS), ITS USE AND METHOD OF CREATING REVERSIBLE PHARMACOLOGICALLY INDUCED HYPOMETABOLISM AND HYPOTHERMIA | 2017 |
|
RU2668374C1 |
| AGENT INCLUDING CYCLIC GLUCOSE OLIGOMER (OPTIONS), ITS APPLICATION AND METHOD OF CREATING REVERSIBLE PHARMACOLOGICALLY INDUCED HYPOMETABOLISM AND HYPOTHERMIA | 2017 |
|
RU2669399C1 |
| USE OF XENON IMMOBILIZED IN CARRIER IN AGENT FOR INCREASING BODY RESISTANCE TO HYPOXIA | 2018 |
|
RU2696100C1 |
| AGENT, ITS APPLICATION AND METHOD FOR IMPROVING RESISTANCE OF MAMMAL ORGANISM TO SUPERCOOLING | 2017 |
|
RU2665963C1 |
| AGENT, ITS USE AND METHOD OF CREATING REVERSIBLE PHARMACOLOGICALLY INDUCED HYPOMETABOLISM AND HYPOTHERMIA | 2017 |
|
RU2669400C1 |
| METHOD OF INHIBITING TUMOUR GROWTH IN MAMMAL | 2018 |
|
RU2713153C1 |
| NOVEL ISOPULEGOL-BASED AGENTS INDUCING HYPOTHERMIA IN ANIMALS | 2023 |
|
RU2814731C1 |
| ANTIDEPRESSANT FOR CORRECTION OF SIDE EFFECTS FROM NEUROLEPTICS | 2019 |
|
RU2746012C2 |
